3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 2
1
Status
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Breast Neoplasms
37
Neoplasm Metastasis
2
Breast Diseases
2
Luminal B/HER2-negative Breast Cancer
1
Hormone Receptor Positive Breast Carcinoma
1
Hormonal Receptors Positive, HER2 Negative, Advanced Breast Cancer
1
HR+/HER2- Early Breast Cancer
1
HR+/HER2+ Early Breast Cancer
1
Estrogen Receptor and/or Progesterone Receptor Positive
1
Endometrial Stromal Tumors
1
Bulbo-Spinal Atrophy, X-Linked
1
Breast Neoplasms, Male
1
Breast Cancer Female
1
Arthralgia
1
Advanced Breast Cancer
1
Interventions
Fulvestrant
9
olaparib
4
Capecitabine
4
pyrotinib
3
Injections
3
Docetaxel
3
trastuzumab deruxtecan
2
toripalimab
2
Vinorelbine
2
Trastuzumab
2
Letrozole
2
Goserelin
2
Alpelisib
2
vandetanib
1
talazoparib
1
sacituzumab govitecan
1
pembrolizumab
1
neratinib
1
liposomal doxorubicin
1
exemestane
1
eribulin
1
dalpiciclib
1
ceralasertib
1
cediranib
1
capivasertib
1
abemaciclib
1
Tablets
1
Paclitaxel
1
Moxifloxacin
1
Lead
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Advanced Breast Cancer
×
Aromatase Inhibitors
×
Clear all
NCT04227327
2025-07-29
HERMIONE-7
University of Milano Bicocca
Phase 2
Terminated
31 enrolled